1. Left ventricular reverse remodeling after combined ARNI and SGLT2 therapy in heart failure patients with reduced or mildly reduced ejection fraction
- Author
-
Michele Correale, Damiano D’Alessandro, Lucia Tricarico, Vincenzo Ceci, Pietro Mazzeo, Raffaele Capasso, Salvatore Ferrara, Massimo Barile, Nicola Di Nunno, Luciano Rossi, Antonio Vitullo, Michele Granatiero, Mattia Granato, Massimo Iacoviello, and Natale Daniele Brunetti
- Subjects
Remodeling ,HFrEF ,Heart failure ,Gliflozins ,SGLT2i ,Sacubitril/Valsartan ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: Cardiac remodeling is an adverse phenomenon linked to heart failure (HF) progression. Cardiac remodeling could represent the real therapeutic goal in the treatment of patients with HF and reduced ejection fraction (HFrEF), being potentially reversed through different pharmacotherapies. Currently, there are well-established drugs such as ACEi/ARBs and β-blockers with anti-remodeling effects. More recently, ARNI effects on cardiac remodeling were also demonstrated; additional potential benefits of gliflozins remain non clearly demonstrated. Aim of study: To evaluate possible changes in cardiac remodeling in patients with HFrEF/HFmrEF in treatment with ARNI or ARNI plus SGLT2i and the potential benefit on cardiac remodeling of adding SGLT2i to ARNI. Methods: Between June 2021 and August 2023, 100 consecutive patients with HFrEF/HFmrEF underwent conventional and advanced echocardiography (TDI, 2DSTE): patients were therefore divided into three groups according to therapy with neither ARNI nor SGLT2i, just ARNI or both. After 3 months, all patients underwent echocardiographic follow-up. Results: After a 3 months of therapy, significant improvements were observed for LVEF, LVEDD, LVEDV, LVESV, LV mass, E/e’, LV GLS, TAPSE (ANOVA p
- Published
- 2024
- Full Text
- View/download PDF